Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 18 1 2019 02 24 80 90 Sarvenaz Kashefi Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Hamid Ahmadi Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran Ramesh Omranipour Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran AND Department of Surgical Oncology, Tehran University of Medical Sciences, Tehran, Iran Habibollah Mahmoodzadeh Department of Surgical Oncology, Tehran University of Medical Sciences, Tehran, Iran Fahimeh Jafarnezhad-Ansariha Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Farzaneh Tofighi Zavareh Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran AND Department of Surgical Oncology, Tehran University of Medical Sciences, Tehran, Iran Abbas Mirshafiey Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran AND Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran 2018 09 28 2018 12 03 With respect to the role of chronic inflammation in the induction and progression of breast cancer (BC). The relationship between tumor and tumor microenvironment may be a hopeful strategy for BC therapy. According to the effect of β-D-Mannuronic acid (M2000) as a novel non-steroidal anti-inflammatory drug (NSAID) on BC murine model and 4T1 cell line, we started to study that was a phase II, randomized, controlled clinical trial. 24 women with BC were included in this study and were followed by fixed oral doses of M2000, 500 mg two times a day (6-8 weeks). Blood samples were collected at baseline and weeks 6-8. To compare the patterns of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), C-C motif chemokine ligand 22 (CCL22) and The transforming growth factor-beta 1 (TGFβ1) gene expression and T regulatory cells (Tregs) frequency of healthy women normal controls with BC patients, a set of 10 blood samples of  women healthy volunteers was collected. The gene expression was evaluated by quantitative Real-time PCR (qRT-PCR) and the frequency of Tregs was assessed by flow cytometry. Our results showed, reduction in MMP-2 (p=0.08), MMP-9 (p=0.03), CCL22 (p=0.003) and TGFβ1 (p=0.1) gene expression and Tregs frequency (p=0.01) which play a main role in the development of chronic inflammation, angiogenesis, tumorigenesis and metastasis. Our findings demonstrated that M2000 therapy as a novel designed NSAID had valuable therapeutic effects on BC. No adverse effects were observed following the use of M2000 after 6-8 weeks. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2157 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/2157/1401